Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Boehringer Ingelheim will spend more than $62 million to build a facility for producing new active pharmaceutical ingredients at the company’s Biberach, Germany, site. The new facility will make clinical-scale quantities of compounds arising from the firm’s own drug development pipeline. The pilot plant facility will have 15 reactors with volumes from 100 to 300 L and four manufacturing bays, including four synthesis labs for scale-up work. Boehringer expects to complete construction of the plant and associated tech center in early 2014.
This article has been sent to the following recipient: